Search form
Search
contact us
Navigation
home
boards
job center
job ratings
cp wire
device news
pharmagather
catering
advertise
Legal Help
login/register
You are here
Home
»
companies
» cemiplimab
cemiplimab
Sanofi says on track to regain solid position in cancer drugs
Sanofi says on track to regain solid position in cancer drugs
Reuters
Sanofi
oncology
immunotherapy
molecular oncology
cemiplimab
Flag link:
5 takeaways from the first look at cancer's biggest conference
5 takeaways from the first look at cancer's biggest conference
Biopharma Dive
ASCO
Regeneron
cemiplimab
Keytruda
Opdivo
Merck
Bristol-Myers Squibb
Nektar
NKTR-214
Loxo Oncology
LOXO-292
Jounce Therapeutics
JTX-2011
Flag link:
Regeneron/Sanofi circle October 28 on the calendar as the FDA begins a speedy review of the world’s 6th PD-1/L1 checkpoint
Regeneron/Sanofi circle October 28 on the calendar as the FDA begins a speedy review of the world’s 6th PD-1/L1 checkpoint
Endpoints
Regeneron
Sanofi
PD-1 inhibitors
FDA
cemiplimab
Flag link:
Regeneron’s coming late to a group of drugs that’s already worth billions — here’s why the company thinks it can still compete
Regeneron’s coming late to a group of drugs that’s already worth billions — here’s why the company thinks it can still compete
SF Gate, CA
Regeneron
PDL-1 inhibitors
cemiplimab
Flag link:
Sanofi and Regeneron boost investment in cancer drug cemiplimab
Sanofi and Regeneron boost investment in cancer drug cemiplimab
Yahoo/Reuters
Sanofi
Regeneron
cemiplimab
cancer
dupilumab
Flag link:
On a new deal spree, Regeneron buys into ISA in pursuit of a checkpoint combo
On a new deal spree, Regeneron buys into ISA in pursuit of a checkpoint combo
Endpoints
Regeneron
ISA
cervical cancer
head and neck cancer
cemiplimab
Flag link:
Will This Drug Kick-Start Regeneron Pharmaceuticals Shares?
Will This Drug Kick-Start Regeneron Pharmaceuticals Shares?
Motley Fool
Regeneron
Sanofi
cemiplimab
skin cancer
Flag link:
Regeneron, Sanofi are ready to debut the 6th PD-1/L1. Is it still possible to stand out from the growing crowd?
Regeneron, Sanofi are ready to debut the 6th PD-1/L1. Is it still possible to stand out from the growing crowd?
Endpoints
Regeneron
Sanofi
anti-PD-L1
cemiplimab
advanced cutaneous squamous cell carcinoma
Flag link:
Sanofi, Regeneron earn ‘breakthrough’ status for a fast-track drug out to prove PD-1 dominance
Sanofi, Regeneron earn ‘breakthrough’ status for a fast-track drug out to prove PD-1 dominance
Endpoints
Sanofi
Regeneron
fast track
breakthrough status
cemiplimab
anti-PD-L1
Flag link: